特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C5aアナフィラトキシン走化性受容体1 (C5aアナフィラトキシン走化性受容体、C5a-R、CD88、C5AR1):パイプライン製品の分析

C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 363563
出版日 ページ情報 英文 66 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
C5aアナフィラトキシン走化性受容体1 (C5aアナフィラトキシン走化性受容体、C5a-R、CD88、C5AR1):パイプライン製品の分析 C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 66 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、世界各国でのC5aアナフィラトキシン走化性受容体1 (またはC5aアナフィラトキシン走化性受容体、C5a-R、CD88、C5AR1) 治療薬のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

  • イントロダクション
    • 分析範囲
  • C5aアナフィラトキシン走化性受容体1 (C5aアナフィラトキシン走化性受容体、C5a-R、CD88、C5AR1) の概要
  • 治療薬の開発状況
    • 治験の段階別
    • 治療領域別
    • 症状別
  • パイプライン製品の概略
    • 後期段階の製品
    • 初期段階の製品
  • 各企業で開発中の治療薬
  • 治療薬の評価
    • 単剤治療薬/併用治療薬の場合
    • 作用機序別
    • 投与方法別
    • 分子の種類別
  • 治療薬の開発に従事している企業
    • AFFiRiS AG
    • ChemoCentryx, Inc.
    • Dompe Farmaceutici S.p.A.
    • Noxxon Pharma AG
  • 薬剤のプロファイル
    • CCX-168
      • 製品概要
      • 作用機序
      • 研究開発 (R&D) の進展状況
    • DF-2593A
    • 歯周病向けC5aR拮抗薬
    • EP-67
    • NOXD-19
    • NOXD-20
    • 未公開の症状向けC5aR標的小分子
    • 筋萎縮性側索硬化症 (ALS) 向けC5aR拮抗用合成ペプチド
    • アルツハイマー病向けC5a標的ワクチン
  • 開発が休止状態の製品
  • 開発が中止された製品
  • 注目すべき最新動向・プレスリリース (全15件)
  • 付録

図表一覧

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Alsonex Pty Ltd, H1 2020
  • Pipeline by ChemoCentryx Inc, H1 2020
  • Pipeline by Dompe Farmaceutici SpA, H1 2020
  • Pipeline by Innate Pharma SA, H1 2020
  • Pipeline by MorphoSys AG, H1 2020
  • Pipeline by Prommune Inc, H1 2020
  • Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2423TDB

Summary:

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Filing rejected/Withdrawn, Phase II and Preclinical stages are 1, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Infectious Disease, Oncology, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Mouth and Dental Disorders and Musculoskeletal Disorders which include indications Autoimmune Disorders, Allergic Asthma, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Churg-Strauss Syndrome, Coronavirus Disease 2019 (COVID-19), Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Pain, Parkinson's Disease, Periodontitis, Pneumonia, Renal Cell Carcinoma, Rheumatoid Arthritis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2020, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
    • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
    • Alsonex Pty Ltd
    • ChemoCentryx Inc
    • Dompe Farmaceutici SpA
    • Innate Pharma SA
    • MorphoSys AG
    • Prommune Inc
    • Teva Pharmaceutical Industries Ltd
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
    • ALS-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer